Current Report Filing (8-k)
March 13 2017 - 7:49AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 13, 2017
Agios Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
|
Delaware
|
|
001-36014
|
|
26-0662915
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
88 Sidney Street, Cambridge, MA
|
|
02139
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (617) 649-8600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
On March 13, 2017, Agios Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that Celgene Corporation (“Celgene”)
has designated the development candidate focused on methylthioadenosine phosphorylase (“MTAP”) deleted cancers as a development candidate under the master research and collaboration agreement between the Company and Celgene, dated
May 17, 2016 (the “Agreement”). Under the terms of the Agreement, Celgene will pay Agios an $8 million designation fee for the MTAP pathway program, which the Company expects to receive in the second quarter of 2017. The full text of
the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
The Company expects that the $8 million designation fee will be deferred and allocated among its performance obligations, identified as part of the Agreement,
and recognized in proportion to the Company’s satisfaction of each performance obligation. The last of these performance obligations are expected to be fully satisfied in the fourth quarter of 2022.
Item 9.01 Financial Statements and Exhibits.
(d)
The following exhibits are included in this report:
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press release issued by Agios Pharmaceuticals, Inc. on March 13, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
AGIOS PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
Date: March 13, 2017
|
|
|
|
By:
|
|
/s/ David P. Schenkein
|
|
|
|
|
|
|
|
David P. Schenkein, M.D.
President and Chief Executive Officer
|
EXHIBIT INDEX
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press release issued by Agios Pharmaceuticals, Inc. on March 13, 2017.
|
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2023 to Apr 2024
